ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Programmable Macrophage Vesicle Based Bionic Self-Adjuvanting Vaccine for Immunization against Monkeypox Virus.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- The landscape of genitourinary cancer vaccines: clinical advances and future opportunities.Journal of advanced research · 2026Review
- Macrophage-induced immunomodulation in oral tissue repair and regeneration: Recent advances and future perspectives.Journal of advanced research · 2026Review
- A deep learning approach for solving a fractional order Monkeypox transmission model using a harmonic neural network optimized with SGDM.Scientific reports · 2026Article
- Concerns and challenges in clinics-guided nanovaccines design and applications.Acta pharmaceutica Sinica. B · 2026Review
- Integrative biochemical and computational analysis of leflunomide-induced redox alterations in Nauphoeta cinerea.Scientific reports · 2025Article
- Lifespan-Regulated CAR-Macrophages from Myeloid Progenitors for Enhanced Colorectal Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Emerging strategies for monkeypox: antigen and antibody applications in diagnostics, vaccines, and treatments.Military Medical Research · 2025Review
- Optimal strategies for managing Hepatitis B Virus (HBV) infection: a comprehensive approach through education, vaccination, and therapy.Scientific reports · 2025Article
- Development of a CTL Epitope-Based Vaccine Targeting Tumor Antigens in Esophageal Cancer: An Immunoinformatic Study.Iranian journal of biotechnology · 2025Article
- Applications of mRNA-Based Therapies in Oncology and Autoimmunity Beyond VaccinationBalkan medical journal · 2025Article
- Development of a candidate mRNA vaccine based on Multi-Peptide targeting VP4 of rotavirus A: an immunoinformatics and molecular dynamics approach.Scientific reports · 2025Article
- MSC-derived extracellular vesicles: Precision miRNA delivery for overcoming cancer therapy resistance.Regenerative therapy · 2025Review
- Next-Generation Vaccine Platforms: Integrating Synthetic Biology, Nanotechnology, and Systems Immunology for Improved Immunogenicity.Vaccines · 2025Review
- Optimal vaccination model of airborne infection under variable humidity and demographic heterogeneity for hybrid fractional operator technique.Scientific reports · 2025Article
- Mpox-XDE: an ensemble model utilizing deep CNN and explainable AI for monkeypox detection and classification.BMC infectious diseases · 2025Article
- Deciphering Host-Virus Interactions and Advancing Therapeutics for Chronic Viral Infection.Viruses · 2025Review
- JAK/STAT signaling as a key regulator of ferroptosis: mechanisms and therapeutic potentials in cancer and diseases.Cancer cell international · 2025Review
- An optimized ensemble grey wolf-based pipeline for monkeypox diagnosis.Scientific reports · 2025Article
- The role of macrophage polarization in ovarian cancer: from molecular mechanism to therapeutic potentials.Frontiers in immunology · 2025Review
- Synergistic effects of recombinant expressed Fowlicidin and Thymosin α1 hybrid peptides in modulating inflammation and infection in avian macrophages.Frontiers in microbiology · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
17 authors.
Funding
Abstract
The emergence of monkeypox has become a global health threat after the COVID-19 pandemic. Due to the lack of available specifically treatment against MPV, developing an available vaccine is thus the most prospective and urgent strategy. Herein, a programmable macrophage vesicle based bionic self-adjuvanting vaccine (AM@AEvs-PB) is first developed for defending against monkeypox virus (MPV). Based on MPV-related antigen-stimulated macrophage-derived vesicles, the nanovaccine is constructed by loading the mature virion (MV)-related intracellular protein (A29L/M1R) and simultaneously modifying with the enveloped virion (EV) antigen (B6R), enabling them to effectively promote antigen presentation and enhance adaptive immune through self-adjuvant strategy. Owing to the synergistic properties of bionic vaccine coloaded MV and EV protein in defensing MPV, the activation ratio of antigen-presenting cells is nearly four times than that of single antigen in the same dose, resulting in stronger immunity in host. Notably, intramuscular injection uptake of AM@AEvs-PB demonstrated vigorous immune-protective effects in the mouse challenge attempt, offering a promising strategy for pre-clinical monkeypox vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.